Effect and Possible Mechanism of Elaiophylin HY1 Against LPS-Induced Neuroinflammation
LIU Man, YANG Ying-lin, ZHANG Shan-shan, LIU Dong-ni, WANG Yue-hua*, DU Guan-hua*
Beijing Key Laboratory of Drug Target Identification and new drug screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China
Abstract：OBJECTIVE To investigate the anti-neuroinflammation effects of elaiophylin elaiophylin1(HY1) on cerebral cortex of LPS induced mice. METHODS BALB/c mice were randomly divided into control group, LPS model group, LPS+HY1 3,10 mg·kg-1 treatment group, and LPS+HY1 10 mg·kg-1 treatment group. After 7 d of administration, mice in LPS model group and HY1 treatment groups were injected with 5 mg·kg-1 LPS intraperitoneally and cerebral cortex tissues were obtained for the following detection after 6h of LPS injection. The levels of IL-1β, IL-6, TNF-α, MCP-1 and ICAM-1 in cerebral cortex tissues were measured by ELISA; the expression of inflammatory pathway-related protein, including COX2, HMGB1 and MyD88 were detected by Western blot. RESULTS Compared with the control group, the levels of inflammatory related factors and proteins including IL-1β,IL-6,TNF-α, MCP-1, ICAM-1, COX2, HMGB1, and MyD88 in cortex tissues of LPS model group were significantly increased (all P<0.01), while HY1 administration could decrease the release of proinflammatory factors, chemokine and adhesion molecules, and downregulate the expression of inflammatory proteins, such as COX2, HMGB1 and MyD88. CONCLUSION HY1 can protect against neuroinflammation in the cerebral cortex tissue of LPS-injured mice and the mechanism may be related to downregulating of COX2, HMGB1 and MyD88 proteins.
刘漫, 杨滢霖, 张姗姗, 刘冬妮, 王月华, 杜冠华. 洋橄榄叶素HY1对LPS诱导小鼠神经炎症的作用及机制探讨[J]. 中国药学杂志, 2021, 56(15): 1215-1219.
LIU Man, YANG Ying-lin, ZHANG Shan-shan, LIU Dong-ni, WANG Yue-hua, DU Guan-hua. Effect and Possible Mechanism of Elaiophylin HY1 Against LPS-Induced Neuroinflammation. Chinese Pharmaceutical Journal, 2021, 56(15): 1215-1219.
O'BRIEN W T, PHAM L, SYMONS G F, et al. The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target[J]. J Neuroinflam, 2020, 17(1): 1-12.
[2]
JAYARAJ R L, AZIMULLAH S, BEIRAM R, et al. Neuroinflammation: friend and foe for ischemic stroke[J]. J Neuroinflam, 2019, 16(1): 1-24.
[3]
CALSOLARO V, EDISON P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions[J]. Alzheimers Dement, 2016, 12(6): 719-732.
[4]
KUSTRIMOVIC N, MARINO F, COSENTINO M. Peripheral immunity, immunoaging and neuroinflammation in Parkinson's Disease[J]. Curr Med Chem, 2019, 26(20): 3719-3753.
[5]
SAXENA S, LAI I K, LI R, et al. Neuroinflammation is a putative target for the prevention and treatment of perioperative neurocognitive disorders[J]. Br Med Bull, 2019, 130(1): 125-135.
[6]
CROWLEY T, CRYAN J F, DOWNER E J, et al. Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions[J]. Brain Behav Immun, 2016, 54: 260-277.
[7]
RUI W, LI S, XIAO H, et al. Baicalein attenuates neuroinflammation by inhibiting NLRP3/caspase-1/GSDMD pathway in MPTP induced mice model of Parkinson's Disease[J]. Int J Neuropsychopharmacol, 2020, 23(11): 762-773.
[8]
GUHA M, MACKMAN N. LPS induction of gene expression in human monocytes[J]. Cell Signal, 2001, 13(2): 85-94.
[9]
JI Y, LIU J, WANG Z, et al. PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway[J]. Cytokine, 2011, 55(3): 409-419.
[10]
HE X, WEI Z, ZHOU E, et al. Baicalein attenuates inflammatory responses by suppressing TLR4 mediated NF-κB and MAPK signaling pathways in LPS-induced mastitis in mice[J]. Int Immunoph, 2015, 28(1): 470-476.
[11]
LEHNARDT S, MASSILLON L, FOLLETT P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway[J]. Proc Natl Acad Sci USA, 2003, 100(14): 8514-8519.
[12]
LU Y C, YEH W C, OHASHI P S. LPS/TLR4 signal transduction pathway[J]. Cytokine, 2008, 42(2): 145-151.
[13]
LOTZE M T, TRACEY K J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal[J]. Nat Rev Immunol, 2005, 5(4):331-342.
[14]
ANDERSSON U, YANG H, HARRIS H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases[J]. Expert Opin Ther Targets, 2018, 22(3): 263-277.
[15]
ZHOU Y L, YAN Y M, LI S Y, et al. 6-O-angeloylplenolin exerts neuroprotection against lipopolysaccharide-induced neuroinflammation in vitro and in vivo[J]. Acta Pharmacol Sin(中国药理学报), 2020, 41(1): 10-21.
[16]
HAN Y, TIAN E, XU D B, et al. Halichoblelide D, a new elaiophylin derivative with potent cytotoxic activity from mangrove-derived Streptomyces sp. 219807[J]. Molecules, 2016, 21(8):1-7.
[17]
LIM H N, JANG J P, HAN J M, et al. Antiangiogenic potential of microbial metabolite elaiophylin for targeting tumor angiogenesis[J]. Molecules, 2018, 23(3): 1-13.
[18]
WANG G, ZHOU P, CHEN X, et al. The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis[J]. Cancer Biol Ther, 2017, 18(8):584-595.
[19]
ZHENG J, WANG J, WANG Q, et al. Targeting castration-resistant prostate cancer with a novel ROR gamma antagonist elaiophylin[J]. Acta Pharm Sin B(药学学报英文版), 2020, 10(12): 2313-2322.
[20]
ZHAO X, FANG Y, YANG Y, et al. Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells[J]. Autophagy, 2015, 11(10):1849-1863.
[21]
CHENG X, YANG Y L, LI W H, et al. Effect of esculin on acute lung injury induced by LPS in mice and possible mechanism[J]. Chin J New Drug(中国新药杂志), 2018, 27(16): 1849-1854.
[22]
SCHAIN M, KREISL WC. Neuroinflammation in neurodegenerative disorders-a Review[J]. Curr Neurol Neurosci Rep, 2017, 17(3): 1-11.
[23]
CAO S N, BAO X Q, SUN H, et al. Microglial Phagocytosis in the Neurodegenerative Diseases[J]. Acta Acad Med Sin(中国医学科学院学报), 2016, 38(2): 228-233.
[24]
THEOHARIDES T C, ASADI S, PATEL A B. Focal brain inflammation and autism[J]. J Neuroinflam, 2013, 10: 46.
[25]
HINOJOSA A E, GARCIA-BUENO B, LEZA J C, et al. CCL2/MCP-1 modulation of microglial activation and proliferation[J]. J Neuroinflam, 2011, 8:77.
[26]
ZHANG K, WANG H, XU M, et al. Role of MCP-1 and CCR2 in ethanol-induced neuroinflammation and neurodegeneration in the developing brain[J]. J Neuroinflam, 2018, 15(1): 1-14.
[27]
YANG R C, QU X Y, XIAO S Y, et al. Meningitic Escherichia coli-induced upregulation of PDGF-B and ICAM-1 aggravates blood-brain barrier disruption and neuroinflammatory response[J]. J Neuroinflam, 2019, 16(1):1-15.
[28]
JANELIDZE S, MATTSSON N, STOMRUD E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease[J]. Neurology, 2018, 91(9): e867-e877.
[29]
RAWAT C, KUKAL S, DAHIYA U R, et al. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management[J]. J Neuroinflam, 2019, 16(1): 1-15.
[30]
PAUDEL Y N, SHAIKH M F, CHAKRABORTI A, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction[J]. Front Neurosci, 2018, 12: 628.
[31]
YANG Y L, CHENG X, LI W H, et al. Kaempferol attenuates LPS-induced striatum injury in mice involving anti-neuroinflammation, maintaining BBB integrity, and down-regulating the HMGB1/TLR4 pathway[J]. Int J Mol Sci, 2019, 20(3): 1-11.
[32]
NARAYANAN K B, PARK H H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways[J]. Apoptosis, 2015, 20(2): 196-209.
2021, Vol. 56 
